January 27, 2022

NANALYSIS SCIENTIFIC CORP.

TERM SHEET

MARKETED OFFERING OF COMMON SHARES

A preliminary short form prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in each of the provinces of Canada, except for the Province of Québec.

The preliminary short form prospectus is still subject to completion. Copies of the preliminary short form prospectus may be obtained from Echelon Wealth Partners Inc. at ecm@echelonpartners.com. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final short form prospectus has been issued.

This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the preliminary short form prospectus, the final short form prospectus and any amendment for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This term sheet shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

Issuer:	Nanalysis Scientific Corp. (the "**Company**").
Issue:	Treasury offering of common shares in the Company (each, a Common Share "**Shares**").
Issue Price:	C$1.10 per Common Share.
Issue Size:	Up to approximately C$10,725,000 (the "**Offering**").
Over-Allotment Option:	The Company will grant the Agent an option to increase the size of the Offering by up to 15.0%, exercisable in whole or in part at any time for a period of 30 days after and including the Closing Date (the "**Over-Allotment Option**").
Form of Offering:	Best efforts marketed offering of Common Shares, subject to a formal agency agreement, including standard industry "material adverse change out", "disaster out", "regulatory out", "market out", "due diligence out" and "breach out" clauses running up to the Closing Date. The Common Shares will be offered (i) by way of short-form prospectus to be filed in each of the provinces of Canada, except for the Province of Québec , and (ii) in the United States pursuant to available exemptions from registration under the United States Securities Act of 1933, as amended, and (iii) as agreed to by the Echelon Wealth Partners Inc. and the Company, outside of Canada and the United States without: (A) giving rise to any requirement under the laws of such jurisdiction to prepare and/or file a prospectus, registration statement or document having similar effect; or (B) creating any ongoing compliance or continuous disclosure obligations for the

ECHELON CAPITAL MARKETS

	Company pursuant to the laws of such jurisdiction. Concurrently with the Offering, the Company will be conducting a non-brokered private placement of up to C$3,000,000 on the same terms as the Offering.
Use of Proceeds:	The Company will use the net proceeds of the Offering for sales and marketing, strategic acquisitions, general and working capital purposes.
Listing:	The Company will apply to list the Common Shares on the TSX Venture. Listing will be subject to the Company fulfilling all of the applicable listing requirements of the TSX Venture.
Eligibility:	The Common Shares shall be eligible for RRSPs, RRIFs, RDSPs, RESPs, TFSAs, and DPSPs.
Lead Agent:	Echelon Wealth Partners Inc. (the "**Agent**").
Agents' Fee:	The Company will pay to the Agents, on the Closing Date, (i) a cash commission equal to 7% of the aggregate gross proceeds received from the sale of the Common Shares, and (ii) a cash fee of C$25,000. In addition, the Company shall issue warrants to the Agent (collectively, the "**Broker Warrants**" and each a "**Broker Warrant**") equal to 7% of the Common Shares sold in the Offering (including the Over-Allotment Option). Each Broker Warrant entitles the holder thereof to acquire one Common Share at a Price of $1.70 for a period of 24 months following the Closing Date. The Company is entitled to a President's List of up to 909,100 Common Shares, which is subject to a reduced commission.
Closing Date:	On or about February 10, 2022.